Methods MM patients participated in a national survey in the UK and were presented with an adapted list of the JLA priorities based on feedback from patients on the Myeloma UK Patient and Carer Research Panel. In the main survey, participants were presented with 10 priorities and asked to ...
The multiple myeloma condition center is a comprehensive resource for clinical news and expert insights on multiple myeloma. Read more at OncLive.
site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit theInternational Myeloma FoundationorHealthTree for Multiple Myeloma....
Multiple Myeloma By Matthew Stenger/November 2024 Effect of Myeloma Therapy in a Patient With Monoclonal Gammopathy of Thrombotic Significance In a letter to the editor in The New England Journal of Medicine, Salmasi et al described identification of monoclonal gammopathy of thrombotic significance (MGT...
Myeloma Canada has a wealth of resources, as well as Myeloma UK [and] Myeloma Europe. And so, I will just look at the geography of where that patient is located for specific resources and try to link them into support groups as well. Faith E. Davies, MD: Excellent. Katie, anything ...
multiple myelomapatient-reported outcomesproteasome inhibitorsrefractory and relapsed diseaseIntroduction: Management of multiple myeloma (MM) has improved over recent years. Health-related quality of life (HRQoL) data is becoming increasingly important, owing to improved survival outcomes. Areas covered: ...
Extent of Prior Therapy Does Not Impact Radiotherapy Response in Myeloma By Russ Conroy April 22nd 2025 Disease control following radiotherapy appeared to be optimal in a retrospective cohort of patients with multiple myeloma. UK’s MHRA Approves Belantamab Mafodotin/Chemo in Myeloma Indications By ...
As novel therapies are expanding the life expectancy of patients with multiple myeloma, appropriate supportive care has become critical in the management o
Multiple myeloma (MM) is a plasma cell malignancy in which monoclonal plasma cells proliferate in bone marrow, resulting in an overabundance of monoclonal paraprotein (M protein), destruction of bone, and displacement of other hematopoietic cell lines.[1]MM is part of a spectrum of diseases rangi...
Hypofractionation Emerges as Standard, but Not Yet for Every Patient Big Moment for Nanotech: Oncology Therapeutics Poised for a Leap The Inflammation Link: NF-κB Remains a Difficult but Intriguing Target Project Aims to "Bridge the Gap" From Remission to Cure in Multiple Myeloma Abirater...